{"id":"d97ee9e2-90bc-5a5f-8b4a-a6c6c1087eda","stable_key":"b7798a90-72a3-5454-a321-c4be88bf0cc4:lithium-ad-short-null","predicate":"no_measured_biomarker_benefit","statement":"A 71-person ten-week AD trial found no treatment effect on CSF biomarkers or lymphocyte GSK3 activity.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"1792da71-611d-5111-8e1f-a3e1e09f1fe2","mechanism_event_label":"A cell mechanism did not translate into measured target effects in this trial.","subject":{"id":"bb5db13c-d287-5847-93b2-98ab0d023797","slug":"lithium-carbonate","display_name":"Lithium carbonate","entity_type_key":"small_molecule"},"object":{"id":"e27ecd1f-c374-51ab-a92b-1ed11ca5cc1b","slug":"human-ad-lithium-tau-gsk3-trial","display_name":"Human AD trial CSF tau and lymphocyte GSK3 outcomes","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1792da71-611d-5111-8e1f-a3e1e09f1fe2","stable_key":"b7798a90-72a3-5454-a321-c4be88bf0cc4:lithium-ad-short-null-event","event_type":"observed_relationship","label":"A cell mechanism did not translate into measured target effects in this trial.","description":"A 71-person ten-week AD trial found no treatment effect on CSF biomarkers or lymphocyte GSK3 activity.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"bb5db13c-d287-5847-93b2-98ab0d023797","slug":"lithium-carbonate","display_name":"Lithium carbonate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"e27ecd1f-c374-51ab-a92b-1ed11ca5cc1b","slug":"human-ad-lithium-tau-gsk3-trial","display_name":"Human AD trial CSF tau and lymphocyte GSK3 outcomes","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"8e2e3902-5e26-52e3-9c85-1d7c0ace1637","slug":"lithium","display_name":"Lithium","entity_type_key":"nutrient_element"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"13b4b09c-4581-58f6-9792-9a78125963e8","slug":"lithium-ion","display_name":"Lithium ion (Li+)","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"9fe71ad0-5696-5db1-b0a6-082cdb115a28","slug":"gsk3b","display_name":"Human glycogen synthase kinase 3 beta / GSK3B","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"e6e12feb-ecfe-5217-8cfd-5184a502cceb","slug":"mapt","display_name":"Human microtubule-associated protein tau / MAPT","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Mild AD; six-week titration; serum target 0.5–0.8 mmol/L.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Short duration and different disease stage; neither proves lifelong efficacy nor rules out every regimen.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lithium","display_name":"Lithium","entity_type_key":"nutrient_element"}},{"dimension":"plain_language","value_text":"A cell mechanism did not translate into measured target effects in this trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19573486/","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"59e47a9e-f9c0-5543-849a-54571ef66bb6","evidence_kind":"source_excerpt","locator":"Lines 552-558","start_line":552,"end_line":558,"excerpt":"## lithium-ad-short-null\nA cell mechanism did not translate into measured target effects in this trial.\nA 71-person ten-week AD trial found no treatment effect on CSF biomarkers or lymphocyte GSK3 activity.\nModel: Mild AD; six-week titration; serum target 0.5–0.8 mmol/L.\nLimitations: Short duration and different disease stage; neither proves lifelong efficacy nor rules out every regimen.\nEvidence access: Primary abstract\nLithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19573486/","model_system":"Mild AD; six-week titration; serum target 0.5–0.8 mmol/L.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b2dd2f3c-5c4c-5a12-9a0d-91b521ffcf98","stable_key":"import-b7798a90-72a3-5454-a321-c4be88bf0cc4","title":"Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"dc67e965ba78458cf2d88d000d687641d9104354115ab16529a3a64941bd777d","revision_id":"4af127bf-9ccc-516b-9481-fafd453c2c35","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}